NSSI Disorder:  Valid Diagnostic Entity?

Jennifer Muehlenkamp, Ph.D.

Introduction

Jennifer J. Muehlenkamp, PhD is a licensed clinical psychologist and Professor of Psychology at the University of Wisconsin-Eau Claire. She received her doctorate from Northern Illinois University after completing her clinical internship within the Child and Adolescent Outpatient Psychiatry Department at Montefiore Medical Center in New York City, specializing in adolescent Dialectical Behavior Therapy. Dr. Muehlenkamp maintained a clinical practice alongside her academic appointments for five years post-graduation. Dr. Muehlenkamp is an internationally renowned leading expert on non-suicidal self-injury and suicide; having published nearly 100 research articles and book chapters on the topic of assessment, treatment, and risk & protective factors. She is a co-author of two books (Non-Suicidal Self-Injury in Eating Disorders and Nonsuicidal Self-Injury: Advances in Psychotherapy) and is a regular consultant to mental and behavioral health professionals in her region. Dr. Muehlenkamp’s work has been honored with awards from the American Association of Suicidology, Self-Injury Awareness Network, and has been featured in U.S. media outlets such as the Wall Street Journal and the American Psychological Association’s newsletter, The APA Monitor. She has received over $2 million dollars in local and federal grants from SAMHSA and the National Institute of Mental Health to support her work. In addition to her research and teaching, Dr. Muehlenkamp is the director of her University’s Suicide Prevention and Research Collaborative, she is a board member of her State and County Suicide Prevention Coalitions, and she is Past-President of the International Society for the Study of Self-Injury.

Learning Objectives

1. Critique the DSM-5 proposed diagnostic criteria for NSSI-disorder.

2. Identify empirically established NSSI frequency cut-offs linked to clinically meaningful distress.

3. Describe a minimum of three features of NSSI associated with increased suicide risk.

Live webcast available at: http://videos.mayo.edu/live
1 AMA PRA Category 1 Credit(s)™ hour is offered for watching this Webcast live. Ethos will be implemented for all post presentation surveys. To document your attendance, please text the code given at the presentation to 507-200-3010. For questions, email rstpsychgr@mayo.edu.

Accreditation Statement

In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Credit Statement(s)

AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

APA
The Department of Psychiatry and Psychology at Mayo Clinic, Rochester, is approved by the American Psychological Association to sponsor continuing education credits for psychologists. The Department of Psychiatry and Psychology at Mayo Clinic, Rochester maintains responsibility for this program and its content.

Archived webcast available at: Psychiatry & Psychology Video Library

Industry Acknowledgment (if applicable): None.

All participants MUST complete the evaluation in order to get CME or APA Credit.

1) Text the CODE announced at the session within 48 hours to (507) 200-3010
2) Login at ce.mayo.edu and go to My Account, My Courses, Registered Courses, click Session title and START to access the required Evaluation.
-or-
Click the START button on that session page.
3) Evaluation must be completed within 2 weeks.

Disclosure Summary
As a provider accredited by Joint Accreditation Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science (Mayo Clinic School of CPD) must ensure balance, independence, objectivity and scientific rigor in its educational activities. Course Director(s), Planning Committee Members, Faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty also will disclose any off label and/or investigational use of pharmaceuticals or instruments discussed in their presentation. Disclosure of these relevant financial relationships will be published in activity materials so those participants in the activity may formulate their own judgments regarding the presentation.
 

Listed below are individuals with control of the content of this program who have disclosed…

Relevant financial relationship(s) with industry:

Mark Frye, M.D. - Mayo Clinic

Grant Support: AssureRx, Janssen R&D, Myriad, Pfizer Consultant: Janssen R&D, Mitsubishi Tanabe Pharma Corp., Myriad Genetics, Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals, Neuralstem, Inc.

CME/Travel: American Physician Institute, CME Outfitters

No relevant financial relationship(s) with industry:
Kriti Gandhi, M.D., Allison Holgerson, Ph.D., Matej Markota, M.D., Charlene Nelson, Reem Shafi, M.B.B.S., Laura Suarez, M.D.

Speaker:  Jennifer Muehlenkamp, Ph.D.

References to off-label usage(s) of pharmaceuticals or instruments in their presentation:

None